The VITALITY 2 system incorporates Guidant's proprietary RHYTHM ID^TM feature, which utilizes rhythm discrimination technology, is designed to distinguish lethal from non-lethal heart rhythms and deliver the appropriate care at the appropriate time.

"Guidant is committed to treatment options that enable physicians to provide optimal therapy for their patients at risk for sudden cardiac death," said Fred McCoy, president, Cardiac Rhythm Management, Guidant Corporation. "The launch of the VITALITY 2 represents an important step forward in our ongoing efforts to help these people live longer."

Full market launch of the VITALITY 2 implantable defibrillator is scheduled for May 2004.

To read more, please click Guidant

Submitted by Michael Johns, DOTmed, Staff Reporter

More Industry Headlines